文献速递食管胃疾病与幽门螺杆菌

2011至2021年美国幽门螺杆菌抗生素耐药性:系统综述与Meta分析

Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Gastroenterol · 2022-05-05

该系统综述与Meta分析检索2011至2021年发表的文献,纳入19项研究共2660份样本,评估美国幽门螺杆菌抗生素耐药率。甲硝唑、左氧氟沙星和克拉霉素耐药率均超过30%,而阿莫西林、四环素和利福布汀耐药率仍较低,但研究间存在明显异质性。

要点

  • 甲硝唑耐药率为42.1%,左氧氟沙星为37.6%,克拉霉素为31.5%,均超过30%。
  • 阿莫西林耐药率为2.6%,四环素为0.87%,利福布汀为0.17%,仍保持较低水平。
  • 在不了解可能耐药模式的情况下选择经验性抗生素方案是不合适的。

核心结论

  • 甲硝唑、左氧氟沙星和克拉霉素耐药率均超过30%,在不了解可能耐药模式的情况下选择经验性抗生素方案是不合适的。
  • 四环素、利福布汀和阿莫西林耐药率仍较低。
  • 鉴于数据稀缺且研究间存在明显异质性,持续监测(最好采用更系统的数据收集方法)是幽门螺杆菌管理中日益重要的目标。

研究设计与样本

  • 系统综述与Meta分析,检索Ovid MEDLINE、Embase、CINAHL和Cochrane CENTRAL数据库中2011至2021年发表的手稿和会议摘要。
  • 纳入19项研究,共2660份样本,报告幽门螺杆菌抗生素耐药性。
  • 采用混合效应模型估计克拉霉素、阿莫西林、甲硝唑、四环素、利福布汀、左氧氟沙星或其组合的合并耐药率及95%置信区间(CI)。

主要发现

  • 甲硝唑合并耐药率为42.1%(95% CI 27.3%-58.6%)。
  • 左氧氟沙星合并耐药率为37.6%(95% CI 26.3%-50.4%)。
  • 克拉霉素合并耐药率为31.5%(95% CI 23.6%-40.6%)。
  • 阿莫西林合并耐药率为2.6%(95% CI 1.4%-5.0%),四环素为0.87%(95% CI 0.2%-3.8%),利福布汀为0.17%(95% CI 0.00%-10.9%)。
  • 克拉霉素与甲硝唑双重耐药合并率为11.7%(95% CI 0.1%-94.0%)。

关键数值与推荐

  • 除利福布汀耐药外,合并耐药率存在明显数据异质性(I² > 50%)。

临床怎么用

  • 甲硝唑、左氧氟沙星和克拉霉素耐药率均超过30%,因此在不了解可能耐药模式的情况下选择经验性抗生素方案是不合适的。

局限性

  • 除利福布汀耐药外,合并耐药率存在明显数据异质性(I² > 50%)。
  • 数据稀缺且研究间存在明显异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Antimicrobial resistance among Helicobacter pylori strains has been rising globally, leading to declining eradication rates. We performed a systematic review and meta-analysis of the resistance patterns of H. pylori strains in the United States between 2011 and 2021. METHODS: Ovid MEDLINE, Embase, CINAHL, and Cochrane CENTRAL databases were searched for manuscripts and conference abstracts published between 2011 and 2021 reporting H. pylori antibiotic resistance. A mixed-effects model estimated pooled rates of resistance to clarithromycin, amoxicillin, metronidazole, tetracycline, rifabutin, levofloxacin, or a combination of these, with 95% confidence intervals (CIs). RESULTS: A total of 19 studies including 2,660 samples, met inclusion criteria. The pooled rate of resistance to metronidazole was 42.1% (95% CI 27.3%-58.6%), levofloxacin 37.6% (95% CI 26.3%-50.4%), clarithromycin 31.5% (95% CI 23.6%-40.6%), amoxicillin 2.6% (95% CI 1.4%-5.0%), tetracycline 0.87% (95% CI 0.2%-3.8%), rifabutin 0.17% (95% CI 0.00%-10.9%), and dual clarithromycin and metronidazole 11.7% (95% CI 0.1%-94.0%). Considerable data heterogeneity was evident for pooled resistance prevalence rates (I 2 > 50%), with the exception of rifabutin resistance. DISCUSSION: Metronidazole, levofloxacin, and clarithromycin resistance rates each exceed 30%; thus, choosing an empiric antibiotic regimen without knowledge of the likely pattern of antibiotic resistance is not appropriate. Resistance to tetracycline, rifabutin, and amoxicillin remains low. Given the scarcity of available data with considerable heterogeneity among studies, continued surveillance, ideally with a more systematic approach to data collection, is an increasingly important goal in H. pylori management.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Ho JJC, Navarro M, Sawyer K, et al. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2022. PMID: 35509128. doi:10.14309/ajg.0000000000001828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。